Michelle Lofwall, MD is a Professor in the Departments of Behavioral Science and Psychiatry and the Bell Alcohol and Addictions Endowed Chair at the University of Kentucky (UK).  She is the medical director of two comprehensive opioid use disorder (OUD) treatment clinics within the UK Center on Drug and Alcohol Research.  Her passion is in improving the care of patients with addiction including in special populations such as pregnant and parenting persons and persons with serious medical and psychiatric comorbidities. She is dedicated to  improving the health literacy of the public, patients, clinicians and policy makers about best clinical practices and the legal rights of persons with opioid use disorder under the Americans with Disabilities Act to access Food and Drug Administration-approved medications to treatment OUD.   Her research has included medications development for OUD (e.g., buprenorphine implants and long-acting subcutaneous injectables), understanding factors associated with medication adherence, improving care delivery of complex patients with OUD, and best practices for linking and retaining persons in care for OUD treatment.  She was elected as a Distinguished Fellow of American Society of Addiction Medicine (ASAM) and the American Psychiatric Association.  She has received numerous teaching and mentoring awards, the Nyswander/Dole (Marie) Award from the American Association for the Treatment of Opioid Dependence and was an expert panel member for SAMHSA’s Treatment Improvement Protocol on Medication Treatment for Opioid Use Disorder (TIP 63).